Establishment Labs (NASDAQ:ESTA) Shares Gap Down – Time to Sell?

Establishment Labs Holdings Inc. (NASDAQ:ESTA) gapped down prior to trading on Tuesday . The stock had previously closed at $31.32, but opened at $30.53. Establishment Labs shares last traded at $31.83, with a volume of 62,015 shares traded.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Stephens reiterated an “overweight” rating and set a $52.00 target price on shares of Establishment Labs in a report on Thursday, March 6th. Needham & Company LLC assumed coverage on shares of Establishment Labs in a research note on Monday. They set a “hold” rating on the stock. Two investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Based on data from MarketBeat, Establishment Labs currently has an average rating of “Moderate Buy” and an average price target of $57.40.

Establishment Labs Stock Performance

The company has a debt-to-equity ratio of 5.94, a quick ratio of 2.29 and a current ratio of 3.62. The company has a 50 day moving average price of $36.51 and a 200 day moving average price of $39.87. The company has a market capitalization of $870.57 million, a PE ratio of -11.70 and a beta of 0.77.

Establishment Labs (NASDAQ:ESTA) last posted its quarterly earnings data on Wednesday, February 26th. The company reported ($0.98) EPS for the quarter, missing analysts’ consensus estimates of ($0.64) by ($0.34). The company had revenue of $44.51 million for the quarter, compared to the consensus estimate of $44.45 million. Establishment Labs had a negative net margin of 46.13% and a negative return on equity of 184.55%. Equities analysts forecast that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Hedge funds and other institutional investors have recently bought and sold shares of the company. Barclays PLC grew its position in shares of Establishment Labs by 9,643.3% in the 3rd quarter. Barclays PLC now owns 31,471 shares of the company’s stock worth $1,362,000 after acquiring an additional 31,148 shares in the last quarter. Assenagon Asset Management S.A. acquired a new position in Establishment Labs in the fourth quarter worth $12,898,000. HighTower Advisors LLC boosted its holdings in Establishment Labs by 32.5% in the third quarter. HighTower Advisors LLC now owns 10,311 shares of the company’s stock worth $446,000 after purchasing an additional 2,529 shares during the period. Raymond James Financial Inc. bought a new stake in Establishment Labs during the fourth quarter valued at $5,494,000. Finally, Swiss National Bank raised its holdings in shares of Establishment Labs by 2.7% during the fourth quarter. Swiss National Bank now owns 38,500 shares of the company’s stock worth $1,774,000 after purchasing an additional 1,000 shares during the period. 72.91% of the stock is owned by institutional investors.

Establishment Labs Company Profile

Establishment Labs Holdings Inc, a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under the Motiva Implants brand. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander.